Immorta Bio Extends Mouse Lifespan by 84% with Novel Dual-Therapy Approach
Event summary
- Immorta Bio's dual-platform therapy combining SenoVax™ and StemCellRevivify™ extended median lifespan by ~84% in aging mouse models.
- The approach also improved healthspan metrics, including physical performance and reduced frailty.
- Research accepted for presentation at AAI's IMMUNOLOGY2026 conference (April 15–19, 2026).
- Company advancing toward IND-enabling studies for human trials, targeting liver disease and cancer first.
The big picture
Immorta Bio's results highlight a growing trend of combining senolytic therapies with regenerative approaches to target aging biology. The acceptance of its research at IMMUNOLOGY2026 underscores the scientific validation of its platform, positioning it among leaders in longevity biotech. Success in human trials could reshape treatment paradigms for age-related diseases.
What we're watching
- Clinical Translation
- Whether the preclinical success will translate to human trials, particularly in liver disease and cancer.
- Regulatory Pathway
- The pace at which Immorta Bio advances IND-enabling studies and secures regulatory approvals.
- Competitive Positioning
- How this dual-therapy approach differentiates Immorta Bio in the crowded longevity therapeutics space.
Related topics
